menu search

Perimeter medical imaging ai initiates new clinical trial site at university of washington's fred hutch cancer center

Perimeter Medical Imaging AI (TSX-V:PINK, OTC:PYNKF) said it has initiated an additional clinical trial site at the Fred Hutch Cancer Center at the U...

October 31, 2023, 8:08 am

Paxmedica’s research on low dose suramin for autism spectrum disorder accepted for publication

TARRYTOWN, N.Y. , Oct. 26, 2023 (GLOBE NEWSWIRE) — via IBN — PaxMedica, Inc. (Nasdaq: PXMD) a clinical-stage biopharmaceutical company, is excited...

October 26, 2023, 5:51 pm

Altimmune to present new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide in a late-breaking presentation at the liver meeting® 2023

GAITHERSBURG, Md., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that n...

October 25, 2023, 7:30 am

Lisata therapeutics announces first patient treated in the cholangiocarcinoma cohort of the bolster trial of lsta1, a novel tumor-targeting and penetrating peptide

Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 in combinati...

October 24, 2023, 12:00 pm

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am

Wall street warms up to tempest as tpst stock surges 1,500%

Tempest Therapeutics (NASDAQ: TPST ) is the stock to watch for today, as its shares are up by a staggering 1,500%. This morning, the cancer therapies ...

October 11, 2023, 12:54 pm

Perimeter medical imaging ai says patient randomization is underway at florida clinical trial site

Perimeter Medical Imaging AI (TSX-V:PINK, OTC:PYNKF) told investors that patient randomization is underway at Mayo Clinic in Florida, the most recent...

October 11, 2023, 8:19 am

Candel therapeutics announces three abstracts accepted for poster presentations at sitc 2023 annual meeting

One clinical poster detailing initial overall survival and immunological biomarker data from the ongoing, rand...

September 27, 2023, 1:40 pm


Search within

Pages Search Results: